keyword
MENU ▼
Read by QxMD icon Read
search

predictive biomarker bevacizumab

keyword
https://www.readbyqxmd.com/read/29910647/antiangiogenic-therapies-in-non-small-cell-lung-cancer
#1
REVIEW
A Alshangiti, G Chandhoke, P M Ellis
Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor performance status, brain metastases, and the presence of bleeding or thrombotic disorders...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29867230/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or-in-combination-with-bevacizumab-versus-sunitinib-in-renal-cell-carcinoma
#2
David F McDermott, Mahrukh A Huseni, Michael B Atkins, Robert J Motzer, Brian I Rini, Bernard Escudier, Lawrence Fong, Richard W Joseph, Sumanta K Pal, James A Reeves, Mario Sznol, John Hainsworth, W Kimryn Rathmell, Walter M Stadler, Thomas Hutson, Martin E Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault-Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S Chen, Priti S Hegde, Christina Schiff, Gregg D Fine, Thomas Powles
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0...
June 2018: Nature Medicine
https://www.readbyqxmd.com/read/29843962/serological-inflammatory-factors-as-biomarkers-for-anatomic-response-in-diabetic-macular-edema-treated-with-anti-vegf
#3
Pedro Brito, Jorge Costa, Nuno Gomes, Sandra Costa, Jorge Correia-Pinto, Rufino Silva
PURPOSE: To study the relationship between systemic pro-inflammatory factors and macular structural response to intravitreal bevacizumab for diabetic macular edema (DME). METHODS: Prospective study including 30 cases with DME, treated with bevacizumab and a minimum follow-up of 6 months. All cases underwent baseline laboratory testing for cardiovascular risk (high sensitivity C-reactive protein (hsCRP), homocystein), dyslipidemia, renal dysfunction and glucose control...
May 11, 2018: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29804638/a-phase-ii-study-of-frontline-paclitaxel-carboplatin-bevacizumab-paclitaxel-carboplatin-temsirolimus-or-ixabepilone-carboplatin-bevacizumab-in-advanced-recurrent-endometrial-cancer
#4
Carol Aghajanian, Virginia Filiaci, Don S Dizon, Jay W Carlson, Matthew A Powell, Angeles Alvarez Secord, Krishnansu S Tewari, David P Bender, David M O'Malley, Ashley Stuckey, JianJiong Gao, Fanny Dao, Robert A Soslow, Heather A Lankes, Kathleen Moore, Douglas A Levine
OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial, patients with chemotherapy-naïve stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) endometrial cancer were randomly assigned to treatment with PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2) or ixabepilone and carboplatin (IC) plus bevacizumab (Arm 3)...
May 24, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29792754/loss-of-chromosome-18q11-2-q12-1-is-predictive-for-survival-in-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab
#5
Erik van Dijk, Hedde D Biesma, Martijn Cordes, Dominiek Smeets, Maarten Neerincx, Sudipto Das, Paul P Eijk, Verena Murphy, Anna Barat, Orna Bacon, Jochen H M Prehn, Johannes Betge, Timo Gaiser, Bozena Fender, Gerrit A Meijer, Deborah A McNamara, Rut Klinger, Miriam Koopman, Matthias P A Ebert, Elaine W Kay, Bryan T Hennessey, Henk M W Verheul, William M Gallagher, Darran P O'Connor, Cornelis J A Punt, Fotios Loupakis, Diether Lambrechts, Annette T Byrne, Nicole C T van Grieken, Bauke Ylstra
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for a biomarker of response to bevacizumab. Previously, we demonstrated that losses of chromosomes 5q34, 17q12, and 18q11.2-q12.1 had a significant correlation with progression-free survival (PFS) in patients with mCRC treated with bevacizumab in the CAIRO2 clinical trial but not in patients who did not receive bevacizumab in the CAIRO trial...
May 24, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29770848/imaging-biomarkers-from-multiparametric-magnetic-resonance-imaging-are-associated-with-survival-outcomes-in-patients-with-brain-metastases-from-breast-cancer
#6
Bang-Bin Chen, Yen-Shen Lu, Chih-Wei Yu, Ching-Hung Lin, Tom Wei-Wu Chen, Shwu-Yuan Wei, Ann-Lii Cheng, Tiffany Ting-Fang Shih
OBJECTIVES: The aim of this study is to investigate the correlation of survival outcomes with imaging biomarkers from multiparametric magnetic resonance imaging (MRI) in patients with brain metastases from breast cancer (BMBC). METHODS: This study was approved by the institutional review board. Twenty-two patients with BMBC who underwent treatment involving bevacizumab on day 1, etoposide on days 2-4, and cisplatin on day 2 in 21-day cycles were prospectively enrolled for a phase II study...
May 16, 2018: European Radiology
https://www.readbyqxmd.com/read/29765225/increased-risk-of-adverse-drug-events-secondary-to-bevacizumab-treatment-in-patients-with-advanced-or-metastatic-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#7
Sooyoung Shin, Yoojin Noh
Background: Several clinical trials have shown an increased risk of hypertension with bevacizumab when added to chemotherapy in different types of malignancy; however, the risks of other significant adverse events besides hypertension, specifically in breast cancer, have not been completely elucidated. This study was conducted with the aim, primarily, to assess the overall incidence and risk of common toxicities associated with bevacizumab in patients with advanced or metastatic breast cancer and, secondarily, to descriptively review study results concerning a potential correlation between bevacizumab-induced hypertension and its efficacy for breast cancer treatment...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29737469/serum-mir-30c-level-predicted-cardiotoxicity-in-non-small-cell-lung-cancer-patients-treated-with-bevacizumab
#8
Fang Zhou, Xike Lu, Xun Zhang
Cardiotoxicity is a common adverse effect induced by drug chemotherapy. miR-30c has been reported to be involved in the progress of heart diseases. In the present study, miR-30c was used to predict the cardiotoxicity in non-small cell lung cancer (NSCLC) patients treated with bevacizumab chemotherapy. Eighty NSCLC patients were included in this study. Serum miR-30c levels were detected at pre-chemotherapy, during-chemotherapy (the 2nd, 4th, and 8th week) and 1 month after chemotherapy. miR-30c expression was elevated with the duration of the chemotherapy cycle and decreased 1 month after chemotherapy...
May 8, 2018: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/29721079/dna-methylation-signatures-predicting-bevacizumab-efficacy-in-metastatic-breast-cancer
#9
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Hubert Hackl, Walter Pulverer, Andreas Weinhaeusel, Suzana Ilic, Clemens Hufnagl, Cornelia Hauser-Kronberger, Alexander Egle, Angela Risch, Richard Greil
Background: Biomarkers predicting response to bevacizumab in breast cancer are still missing. Since epigenetic modifications can contribute to an aberrant regulation of angiogenesis and treatment resistance, we investigated the influence of DNA methylation patterns on bevacizumab efficacy. Methods: Genome-wide methylation profiling using the Illumina Infinium HumanMethylation450 BeadChip was performed in archival FFPE specimens of 36 patients with HER2-negative metastatic breast cancer treated with chemotherapy in combination with bevacizumab as first-line therapy ( learning set )...
2018: Theranostics
https://www.readbyqxmd.com/read/29673151/tumor-molecular-profiling-for-an-individualized-approach-to-the-treatment-of-hepatocellular-carcinoma-a-patient-case-study
#10
Kristine Posadas, Anita Ankola, Zhaohai Yang, Nelson S Yee
Hepatocellular carcinoma (HCC) is increasing in incidence, and the associated mortality rate remains among the highest. For advanced HCC, sorafenib has been shown to slightly prolong survival, and regorafenib and nivolumab, both recently approved by the United States Food and Drug Administration (FDA), may produce clinical benefits to a limited extent. Systemic chemotherapy has been shown to produce a modest response, but there is no clinically valid biomarker that can be used to predict which patients may benefit...
April 17, 2018: Biomedicines
https://www.readbyqxmd.com/read/29657584/dynamic-biomarkers-of-response-to-antiangiogenic-therapies-in-colorectal-cancer-a-review
#11
REVIEW
Jesus Rodriguez-Pascual, Antonio Cubillo
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body. Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice...
December 2017: Current Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/29594657/a-predictive-value-of-von-willebrand-factor-for-early-response-to-bevacizumab-therapy-in-recurrent-glioma
#12
Andrea Pace, Chiara Mandoj, Anna Antenucci, Veronica Villani, Isabella Sperduti, Beatrice Casini, Mariantonia Carosi, Alessandra Fabi, Antonello Vidiri, Tatiana Koudriavtseva, Laura Conti
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was to investigate the possible predictive value of baseline demographic, clinical and laboratory parameters for early 3-month response to BV therapy in patients with recurrent glioma. Forty-nine patients with recurrent glioma received BV at 10 mg/kg intravenously every 3 weeks alone or in association with chemotherapy were included in this study...
March 28, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29573206/identification-of-transcriptome-signature-for-predicting-clinical-response-to-bevacizumab-in-recurrent-glioblastoma
#13
Seung Won Choi, Hyemi Shin, Jason K Sa, Hee Jin Cho, Harim Koo, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam
Glioblastomas are among the most fatal brain tumors. Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor. We retrospectively reviewed patients with recurrent GBM who received bevacizumab to identify biomarkers for predicting clinical response to bevacizumab. Following defined criteria, the patients were categorized into two clinical response groups, and their genetic and transcriptomic results were compared...
May 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29535825/tumour-vasculature-immaturity-oxidative-damage-and-systemic-inflammation-stratify-survival-of-colorectal-cancer-patients-on-bevacizumab-treatment
#14
Sinead A Noonan, Maria E Morrissey, Petra Martin, Monika Biniecka, Shane Ó'Meachair, Aoife Maguire, Miriam Tosetto, Blathnaid Nolan, John Hyland, Kieran Sheahan, Diarmuid O'Donoghue, Hugh Mulcahy, David Fennelly, Jacintha O'Sullivan
Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab plus chemotherapy, response rates are modest and there are no biomarkers available that will predict response. The aim of this study was to assess if markers associated with three interconnected cancer-associated biological processes, specifically angiogenesis, inflammation and oxidative damage, could stratify the survival outcome of this cohort. Levels of angiogenesis, inflammation and oxidative damage markers were assessed in pre-bevacizumab resected tumour and serum samples of mCRC patients by dual immunofluorescence, immunohistochemistry and ELISA...
February 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29467925/plasma-ykl-40-as-a-biomarker-for-bevacizumab-efficacy-in-patients-with-newly-diagnosed-glioblastoma-in-the-phase-3-randomized-avaglio-trial
#15
Mogens K Boisen, Camilla B Holst, Nicola Consalvo, Olivier L Chinot, Julia S Johansen
YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab. Plasma samples were collected from 563 patients in the randomized, phase 3 AVAglio trial who received bevacizumab or placebo plus radiotherapy/temozolomide. Raw plasma YKL-40 concentrations were converted to age-corrected percentiles of normal healthy YKL-40 levels and divided into quartiles (Q). The impact of baseline plasma YKL-40 level on survival was investigated using Cox regression analyses...
January 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29438092/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-nonsquamous-non-small-cell-lung-cancer
#16
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck
LESSONS LEARNED: The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents...
February 7, 2018: Oncologist
https://www.readbyqxmd.com/read/29424297/use-of-immunotherapy-to-treat-metastatic-breast-cancer
#17
Andrea Nicolini, Vivian Barak, Piermario Biava, Paola Ferrari, Giuseppe Rossi, Angelo Carpi
This article reviews the principal attempts of immune-modulation or immune therapy in metastatic breast cancer. It considers their rationale and reports on results from the relevant key clinical trials. Immune-modulatory or immune-stimulating cytokines used alone or combined with conventional therapies is among the principal approaches of immune manipulation in breast cancer. As this issue was recently reviewed by us, the aim of the current article is to discuss our updated and unpublished data on this topic...
February 9, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29410027/pro-metastatic-activity-of-agr2-interrupts-angiogenesis-target-bevacizumab-efficiency-via-direct-interaction-with-vegfa-and-activation-of-nf-%C3%AE%C2%BAb-pathway
#18
Mengqi Jia, Yanxia Guo, Deyu Zhu, Nianzhao Zhang, Lin Li, Jin Jiang, Yiwen Dong, Qingqing Xu, Xiulei Zhang, Meijuan Wang, Haina Yu, Fang Wang, Keli Tian, Jinsan Zhang, Charles Y F Young, Hongxiang Lou, Huiqing Yuan
Anterior gradient 2 (AGR2), an endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI), is associated with cancer development and malignant progression. Here, we show that high level of AGR2 promotes the aggressive phenotype of prostate cancer (PCa) mouse models developed by either patient-derived xenografts or surgical intra-prostate implantation of PCa cells, associated with enrichment of the blood vessel network in tumor tissues. Angiogenesis markers VEGFR2 and CD34, accompanied with the invasive marker Vimentin, were predominantly stained in metastatic liver tissues...
May 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29393706/biomarkers-in-recurrent-grade-iii-glioma-patients-treated-with-bevacizumab-and-irinotecan
#19
REVIEW
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm, Hans Skovgaard Poulsen
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort...
February 7, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29361687/circulating-plasma-levels-of-mir-20b-mir-29b-and-mir-155-as-predictors-of-bevacizumab-efficacy-in-patients-with-metastatic-colorectal-cancer
#20
Paola Ulivi, Matteo Canale, Alessandro Passardi, Giorgia Marisi, Martina Valgiusti, Giovanni Luca Frassineti, Daniele Calistri, Dino Amadori, Emanuela Scarpi
Targeting angiogenesis in the treatment of colorectal cancer (CRC) is a common strategy, for which potential predictive biomarkers have been studied. miRNAs are small non-coding RNAs involved in several processes including the angiogenic pathway. They are very stable in biological fluids, which turns them into potential circulating biomarkers. In this study, we considered a case series of patients with metastatic (m) CRC treated with a bevacizumab (B)-based treatment, enrolled in the prospective multicentric Italian Trial in Advanced Colorectal Cancer (ITACa)...
January 20, 2018: International Journal of Molecular Sciences
keyword
keyword
93667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"